A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carncinoma (HNSCC)

Trial Profile

A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carncinoma (HNSCC)

Suspended
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cisplatin
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jul 2017 Status changed from recruiting to suspended because of Scheduled Interim Monitoring
    • 20 Apr 2017 Status changed from suspended to recruiting.
    • 30 Mar 2017 Status changed from recruiting to suspended as Interim Monitoring is scheduled
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top